A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable Non-small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

Volumn 4, Issue 6, 2009, Pages 722-727

  Jain, Anshu K ^a   Hughes, Randall S ^b   Sandler, Alan B ^c   Dowlati, Afshin ^d   Schwartzberg, Lee S ^e   Dobbs, Tracy ^f   Schlabach, Larry ^g   Wu, Jean ^a   Muldowney, Nancy J ^c   Choy, Hak ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e WEST CLINIC   (United States)

^f Tennessee Cancer Specialists   (United States)

^g University Oncology and Hematology Associates   (United States)

Author keywords

Carboplatin; Chemoradiation; Chemoradiotherapy; Concurrent chemoradiation; Consolidation; Docetaxel; Non small cell lung cancer; NSCLC

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; SEROTONIN 3 AGONIST; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CANCER GROWTH; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOLOGY; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING; ADENOCARCINOMA; LARGE CELL CARCINOMA; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 67849121788     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a5275c     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact oftumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986;12:539-547. (Pubitemid 16081614)
3. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58.
4. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
5. Sause WT, Scott C, Taylor S, et al. Radiation therapy oncology group (RTOG) 88-08 and eastern cooperative oncology group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
6. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215. (Pubitemid 26302034)
7. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699. (Pubitemid 29415225)
8. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621. Abstract 2499.
9. Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98. (Pubitemid 39201387)
10. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004;18:CD002140.
11. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe lyonsaint- etienne d'oncologie thoracique-groupe francais de pneumo-cancerologie npc 95-01 study. J Clin Oncol 2005;23:5910-5917. (Pubitemid 46300207)
12. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92:1074-1080. (Pubitemid 30616481)
13. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-157. (Pubitemid 30105654)
14. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-smallcell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891. (Pubitemid 46300204)
15. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16:3316-3322. (Pubitemid 28481627)
16. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998;4:1931-1936. (Pubitemid 28369177)
17. Choy H, Devore RF III, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a vanderbilt cancer center affiliate network study). Int J Radiat Oncol Biol Phys 2000;47:931-937. (Pubitemid 30345590)
18. Akerley W, Herndon JE Jr, Lyss AP, et al. Induction paclitaxel/ carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study-CALGB 9534. Clin Lung Cancer 2005;7:47-53. (Pubitemid 41150473)
19. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (taxol) and docetaxel (taxotere) in hela and sq20b cells. Cancer Res 1996;56:1842-1850. (Pubitemid 26118220)
20. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3:2431-2438. (Pubitemid 28133165)
21. Amorino GP, Hamilton VM, Choy H. Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Investig 1999;7:343-352. (Pubitemid 30033353)
22. Mason K, Staab A, Hunter N, et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 2001;18:599-606.
23. Gumerlock PH, Mack PC, Manorek GH, et al. Bcl2 phosphorylation and p27 induction as potential p53-independent mechanisms of apoptotic responses to taxanes in non-small cell lung carcinoma (NSCLC). Proc Am Assoc Cancer Res 1999;40:739. Abstract 4879.
24. Ringel I, Horwitz SB. Studies with rp 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
25. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994;12:169-182. (Pubitemid 24376401)
26. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998;5:249-255. (Pubitemid 28039857)
27. Diaz JF, Andreu JM. Assembly of purified gdp-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-2755.
28. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (taxotere). Semin Oncol 1995;22:3-16.
29. Von Hoff DD. The taxoids: same roots, different drugs. Semin Oncol 1997;24:S13-3-S13-10.
30. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104:121-129. (Pubitemid 36184155)
31. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIb non-small-cell lung cancer: phase II southwest oncology group study s9504. J Clin Oncol 2003;21: 2004-2010. (Pubitemid 46606390)
32. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIb non-small-cell lung cancer: a phase II southwest oncology group study (s9504). Clin Lung Cancer 2006;8:116-121. (Pubitemid 44596753)
33. Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys 1999;43:107-114. (Pubitemid 29065839)
34. Choy H, De Vore RF, Hande KR, et al. A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non small-cell lung cancer: a vanderbilt cancer center affiliate network (VCCAN) trial. Clin Lung Cancer 2000;1(Suppl 1):S27-S31.
35. Choy H, DeVore RF, Hande KR, et al. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 2001;34:441-449. (Pubitemid 33041480)
36. Aamdal S, Hallen MN, Tonelli D, Lauvvang G, Owre K, Hatlevoll R. Docetaxel (taxotere) combined with radiation in locally advanced nonsmall- cell lung cancer (NSCLC)-a phase I/II study. Proc Am Soc Clin Oncol 1998;17:476a. Abstract 1830.
37. Koukourakis MI, Kourousis C, Kamilaki M, et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 1998;34:838-844. (Pubitemid 28248494)
38. Murakami H, Kubota K, Ohe Y, et al. Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC). Lung Cancer 2000;29(Suppl 1). Abstract 367.
39. Wirth LJ, Lucca J, Ostler P, et al. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res 2003;9:1698-1704. (Pubitemid 36554593)
40. Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9010. J Clin Oncol 2002;20:3454-3460.
41. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel(D) in patients (PTS) with inoperable stage III non-small cell lung cancer (NSCLC): Hog lun 01-24/uso-023. Proc Am Soc Clin Oncol 2007;25:391s. Abstract 7528.
42. Sakai H, Yoneda S, Kobayashi K, et al. Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 2004;43:195-201. (Pubitemid 38114748)